News

A new study shows disproportionate impact of the virus to this group.

As researchers develop ways to assess the effects of the pandemic on criminal activity, a new report documents the impact on those incarcerated.

These vital cells that are recovered from COVID-19 patients might be able to help people with compromised immune systems due to cancer therapy or transplantation.

While this trial for hospitalized COVID-19 patients has been discontinued, Lilly is continuing their other trials with the medication for COVID-19 treatment.

A research team recently focused on how the pandemic intensifies the effects felt by those already marginalized or vulnerable, as it is the intersection of biological and socioecological factors.

Invasive C glabrata found to be most prevalent strain of Candida in stool of patients with C difficile infection, and likely resistant to caspofungin.

A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.

A case study examines a treatment for a hospitalized case of the virus.

Autoantibodies that attack type 1 interferons, neutralizing the immune system’s ability to block the SARS-CoV-2 virus, were present in 10% of patients with life-threatening coronavirus diseases 2019 (COVID-19) pneumonia, a new study found.

Why it may be more prudent for prescribing clinicians to assume viral, rather than bacterial, infection while awaiting test results in presenting pediatric cases.

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.

The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.

A cross-specialty collaboration to mitigate inpatient cases of opioid use disorder has had early success; developers want to grow it.

An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.

Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

Investigators wanted to examine spontaneously reported adverse events and whether they were cause for concern.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

Here is a look at the patterns within the variety of symptoms and presentations during physician exams.

A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.

The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

Reports of hospitalized older adults with COVID-19 who do not experience the classic symptoms are on the rise.

“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.